Clinical Trial

Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins

Recruiting
View on ClinicalTrials.gov →
Summary
The study aims to reduce the PTV (Planning Target Volume) safety margins to 1-2 mm in stereotactic prostate radiotherapy for low- and medium-risk prostate cancers while maintaining a dose of 36.25 Gy in 5 fractions per day. By reducing the hems, the investigators expect a reduction of acute and late toxicity on the organs at risk, dominantly the urethra, bladder, penile bulb, and rectum, and an improvement in the quality of life.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-29.
Status change: Not Yet Recruiting → Recruiting 2024-11-07
Trial Details
NCT Number NCT06665932
Lead Sponsor University Hospital Ostrava
Conditions Prostate Cancer (Adenocarcinoma)
Enrollment 100 participants
Start Date 2024-11-01
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-12